Brent Saunder’s Vesper Healthcare Acquisition Corp. wants to raise up to $460m in a forthcoming IPO to buy companies in health care and medical market niches including wellness.

Nestle agrees to acquire Aimmune Therapeutics, maker of a drug indicated to reduce the severity of children’s allergic reactions to peanuts. It anticipates options to innovate in its consumer health children’s allergy business.

Takeda is to offload its sizable Japanese OTC operation to private-equity firm Blackstone, which has committed to making the business the country's leading consumer health player.

National Advertising Review Board says P&G’s #1” claim in a shield-shaped logo on Oral-B Precision Clean Interdental Picks package fronts “is adequately connected to the explanatory information," which states “from the makers of the #1 dentist recommended floss brand.”

Fitbit will launch its new Fitbit Sense smartwatch with ECG app in Europe, US, Hong Kong and India in October. 

NAD advises VGH Solutions to pull pain relief claims and statements that am OTC device with FDA 510(k) clearance treats conditions including neuropathy. The firm offered studies and a Health Canada statement listing indications for the device to support claims not part of the US approved indication.

Brent Saunder’s Vesper Healthcare Acquisition Corp. wants to raise up to $460m in a forthcoming IPO to buy companies in health care and medical market niches including wellness.

Germany's PharmaSGP reported solid sales gains in the first half as European consumers snapped up its chemical-free OTCs and dietary supplement offering.

Germany's Stada posts 22% jump in first half sales thanks to recent deals and reveals that more acquisitions may soon follow.

A class action complaint in California’s Southern District, challenging the hand sanitizer manufacturer’s 99.99% germ-kill claim, ignores the asterisk on products’ primary display panels that links to a disclosure on rear labels, “*Effective at eliminating 99.99% of many common harmful germs & bacteria," according to Vi-Jon's 27 August motion to dismiss.

A growing number of class action complainants allege that 99.99% germ-killing claims on hand sanitizers are false and misleading. The suits cite potentially dangerous microorganisms that, according to plaintiffs, are impervious to active ingredients used in the category, and argue that bacteria reductions do not necessarily translate to illness or infection prevention.

Many materials subject to order, APIs needed for OTC as well as Rx drugs, are supplied by companies outside the US, and China accounts for the bulk of them. The order didn't specify countries and products, leaving decisions to FDA.